Kindstar Globalgene Technology (HKSE:09960) ROCE %: -0.17% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09960 Kindstar Globalgene Technology Inc HKSE:09960
69 GF Score
Price HK$1.00
GF Value HK$1.06
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Kindstar Globalgene Technology ROCE %?

Kindstar Globalgene Technology HKSE:09960 +3.09% 69 ROCE % is -0.17% as of Dec. 2025. GuruFocus rates HKSE:09960 with a GF Score™ of 69/100 and a GF Value™ of HK$1.06 (Fairly Valued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kindstar Globalgene Technology's annualized ROCE % for the quarter that ended in Dec. 2025 was -0.17%.

Kindstar Globalgene Technology  (HKSE:09960) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kindstar Globalgene Technology ROCE % Related Terms

Kindstar Globalgene Technology ROCE % Historical Data

* Premium members only.

The historical data trend for Kindstar Globalgene Technology's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kindstar Globalgene Technology ROCE % Chart

Kindstar Globalgene Technology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -77.46 2.93 1.76 -1.52 -0.87

Kindstar Globalgene Technology Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 1.32 -4.35 -1.55 -0.17
HKSE:09960
69GF Score
Kindstar Globalgene Technology Inc HKSE:09960
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kindstar Globalgene Technology ROCE % Calculation

Kindstar Globalgene Technology's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-28.146/( ( (4030.319 - 912.267) + (4147.71 - 815.081) )/ 2 )
=-28.146/( (3118.052+3332.629)/ 2 )
=-28.146/3225.3405
=-0.87 %

Kindstar Globalgene Technology's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-5.516/( ( (4267.572 - 916.057) + (4147.71 - 815.081) )/ 2 )
=-5.516/( ( 3351.515 + 3332.629 )/ 2 )
=-5.516/3342.072
=-0.17 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -0.17% mean?
Kindstar Globalgene Technology (HKSE:09960) has a ROCE % of -0.17% as of Dec. 2025.
Is Kindstar Globalgene Technology's ROCE % too high?
Kindstar Globalgene Technology's current ROCE % is -0.17%. Overall, Kindstar Globalgene Technology has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kindstar Globalgene Technology's ROCE % compare to TMO and DHR?
Kindstar Globalgene Technology's ROCE % of -0.17% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Kindstar Globalgene Technology's current ROCE % is -0.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kindstar Globalgene Technology stock overvalued right now?
Based on GuruFocus' analysis, Kindstar Globalgene Technology (HKSE:09960) is currently considered Fairly Valued. The stock's GF Value™ is HK$1.06, compared to a current price of HK$1.00 — trading 5.7% below its estimated fair value. The current ROCE % is -0.17%. Kindstar Globalgene Technology's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Kindstar Globalgene Technology (HKSE:09960), the current ROCE % is -0.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kindstar Globalgene Technology (HKSE:09960) Overvalued in 2026?

Based on GuruFocus' analysis, Kindstar Globalgene Technology stock appears to be undervalued. The current stock price of HK$1.00 is trading 5.7% below its estimated GF Value™ of HK$1.06. GuruFocus considers Kindstar Globalgene Technology to be Fairly Valued.

Key valuation signals for HKSE:09960:

  • ROCE %: -0.17%
  • GF Value™: HK$1.06 vs. price of HK$1.00 (5.7% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the HKSE:09960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kindstar Globalgene Technology Business Description

Address Biolake D2-1, 666 Gaoxin Road, East Lake High Tech Zone, Hubei Province, Wuhan, CHN
Kindstar Globalgene Technology Inc is engaged in the provision of clinical testing services in China. It operates in nine segments: Hematology testing segment includes testing services related to blood diseases; Genetic diseases and rare diseases segment includes testing services for rare diseases; Infectious diseases segment includes testing services from the infection department; Oncology segment includes testing related to oncology diseases; Neurology segment includes testing services related to neurological diseases undertaken by the Group; Maternity-related diseases segment includes testing services related to maternity; Routine testing segment conducts routine tests for the doctors daily diagnoses; CROs & R&D project segment includes research & develop services; & others segment.
69GF Score

Get the complete analysis for HKSE:09960

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$1.00
Price
HK$1.06
GF Value